Fitzsimons Joanna, Berk Michael, Lambert Timothy, Bourin Michel, Dodd Seetal
Department of Clinical and Biomedical Sciences, Barwon Health, Swanston Centre, University of Melbourne, PO Box 281, Geelong, Victoria 3220, Australia.
Expert Opin Drug Saf. 2005 Jul;4(4):731-44. doi: 10.1517/14740338.4.4.731.
Clozapine is a distinctive antipsychotic agent, having a unique clinical profile and an idiosyncratic safety profile. More so than with other agents, the weighting of its adverse event profile is critical, in order to counterbalance its clear clinical advantages. The safety issues with clozapine are in a number of areas, some of which are considered medical emergencies and potentially life-threatening. These include haematological (neutropenia and agranulocytosis), CNS (seizures), cardiovascular (myocarditis and cardiomyopathy), metabolic (diabetes), gastrointestinal and neuromuscular. Understanding the safety profile of clozapine allows an informed use of the agent that can maximise its clear clinical benefit and minimise the known risks.
氯氮平是一种独特的抗精神病药物,具有独特的临床特征和特殊的安全性特征。与其他药物相比,其不良事件特征的权衡更为关键,以便抵消其明显的临床优势。氯氮平的安全问题涉及多个领域,其中一些被视为医疗紧急情况且可能危及生命。这些领域包括血液学(中性粒细胞减少和粒细胞缺乏症)、中枢神经系统(癫痫发作)、心血管系统(心肌炎和心肌病)、代谢(糖尿病)、胃肠道和神经肌肉方面。了解氯氮平的安全性特征有助于明智地使用该药物,从而最大程度地发挥其明显的临床益处并将已知风险降至最低。